Menu

Precision Medicine in Oncology: No Two Tumors Alike

The Scientist is bringing together a panel of experts to explore where precision oncology is currently positioned in cancer therapy and to discuss where it could be going.

Jun 5, 2019
The Scientist Creative Services Team

FREE Webinar

Wednesday, July 24, 2019
2:30-4:00 PM Eastern Time
Register Now

Most cancers arise from abnormal genes or gene regulation. These abnormalities can occur through inheritance, from environmental insults, or via random mutation. The genetic changes that allow tumors to grow and spread differ between individuals even when they have the same cancer type and stage. Therefore, two people with the same cancer type given the same therapeutic may respond differently based on their cancer’s genetics. Precision medicine allows more targeted therapies, leveraging genetic information about tumor pathogenesis. The precision medicine approach, however, is not yet part of routine care for most cancer patients. To explore where precision oncology is currently positioned in cancer therapy, and to discuss where it could be going, The Scientist is bringing together a panel of experts in the field for this free educational webinar.

Topics to be covered:

  • How to Make Precision Oncology More Precise
  • Toward Precision Medicine - Building a Knowledge Network

Register Now

Meet the Speakers:

Sofia Merajver, MD, PhD
Professor, Epidemiology, and Dept. of Internal Medicine
Director, Breast and Ovarian Cancer Risk and Evaluation Program
University of Michigan, School of Public Health

India Hook-Barnard, PhD
Director of Research Strategy
Associate Director, UCSF Precision Medicine
University of California, San Francisco

 

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.